Intraperitoneal topoisomerase-I inhibitors: Preliminary findings with 9-aminocamptothecin

Annals of the New York Academy of Sciences

Volumn 922, Issue , 2000, Pages 178-187

  Muggia, Franco ^a   Liebes, Leonard ^a   Potmesil, Milan ^a   Hamilton, Anne ^a   Hochster, Howard ^a   Hornreich, Gila ^a   Sorich, Joan ^a   Downey, Andrea ^a   Wasserstrom, Heather ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR;

ADULT; AGED; AREA UNDER THE CURVE; CLINICAL ARTICLE; COMPARTMENT MODEL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; NEUTROPENIA; OVARY CARCINOMA; PLEURA EFFUSION; PRELIMINARY COMMUNICATION; STOMACH CARCINOMA; TREATMENT OUTCOME;

EID: 0034508140     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb07036.x     Document Type: Conference Paper

References (48)

1. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer
2. Pharmacokinetic problems in peritoneal drug administration: Tissue penetration and surface exposure
3. Regional chemotherapy
4. Peritoneal carcinomatosis: Natural history and rational therapeutic intervention using intraperitoneal chemotherapy
5. Regional treatment strategies for unresectable primary and metastatic cancer confined to the liver
6. Camptothecins with lipophilic moiety as potential tools in regional chemotherapy
7. Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavity
8. Intraperitoneal therapy with fluoropyrimidines in the treatment of ovarian and gastrointestinal cancers
9. Intraperitoneal-administered carboplatin in patients with ovarian cancer: Influence of a dwell time on toxicity and response
10. Phase II trial of intraperitoneal carboplatin in ovarian carcinoma patients with macroscopic disease at second laparotomy: A multicentre study of French Federation Nationale des Centres Lutte Contre le Cancer
11. Intraperitoneal carboplatin: Favorable results in women with minimal residual ovarian cancer after cisplatin therapy
12. Intraperitoneal mitoxantrone or floxuridine: Effects on time-to-failure and survival of patients with minimal residual ovarian cancer after second-look laparotomy - A randomized Phase II study by the Southwest Oncology Group
13. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer
14. Intraperitoneal therapy of ovarian cancer
15. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer
16. Phase I trial of intraperitoneal taxol: A Gynecologic Oncology Group study
17. Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy
18. Phase I/II study of intraperitoneal floxuridine and platinums (cisplatin and/or carboplatin)
19. Intraperitoneal 5-fluoro-2′-deoxyuridine with escalating doses of leucovorin: Pharmacology and clinical tolerance
20. Intraperitoneal topotecan with standard iv paclitaxel in ovarian cancer is feasible
21. Structure activity study of the actions of camptothecin derivatives on mammalian topoisomerase I. Evidence for a specific receptor site and for a relation to antitumor activity
22. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogs
23. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts
24. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin
25. Preclinical studies of DNA topoisomerase I-targeted 9-amino and 10,11-methylenedioxy camptothecins
26. Preclinical and clinical development of DNA topoisomerase I inhibitors in the United States
27. Growth inhibition of human cancer metastases by camptothecins in newly developed xenograft models
28. Relationship between the schedule dependence of 9-amino-20(S)-camptothecin (AC; NSC 603071) antitumor activity in mice and its plasma pharmacokinetics
29. Camptothecins: From bench research to hospital wards
30. Phase I trial of colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour intravenous infusion
31. Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks
32. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin
33. Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hr infusion in adult cancer patients
34. Pharmacokinetics and pharmacodynamics of a 72-hr infusion of 9-aminocamptothecin in adult patients
35. 9-Aminocamptothecin and beyond: Preclinical and clinical studies
36. A Phase I study of 9-amino-camptothecin (9-AC) by prolonged infusion of 21 days
37. Phase I and pharmacodynamic study of prolonged infusion of 9-amino-camptothecin (9-AC) in two formulations
38. Phase I trial of low dose continuous topotecan infusion in patients with cancer: An active and well-tolerated regimen
39. Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors
40. Pharmacokinetics of tritium labeled camptothecin in nude mice
41. Novel camptothecins with lipophilic moieties
42. Cellular pharmacokinetics and cytoxicity of camptothecin and topotecan at normal and acidic pH
43. A Phase I study of intraperitoneal administration of 9-amino-20(S)-camptothecin to patients with cancer predominantly confined to the peritoneal cavity
44. Peritoneal access devices for intraperitoneal chemotherapy
45. Analysis of the active lactone form of 9-aminocamptothecin in plasma using solid-phase extraction and high-performance liquid chromatography
46. Liquid chromatography analysis of 9-amino-camptothecin in plasma monitored by fluorescence induced upon postcolumn acidification